Emerson Wealth’s AbbVie ABBV Stock Holding History

Emerson Wealth’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$92K	Hold	600	–	–	0.06%	30
2022 Q1	$97K	Buy	+600	New	+$87.2K	0.05%	31

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Emerson Wealth's ABBV Position: Q2 2022 in Review

Emerson Wealth held its AbbVie (ABBV) position steady in Q2 2022 at 600 shares worth $92K. The position accounts for 0.06% of the portfolio, ranked #30.

Emerson Wealth first reported a position in ABBV in Q1 2022 and has held it in 2 quarters since. The position peaked at $97K in Q1 2022. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

Emerson Wealth held 600 shares of AbbVie worth $92K as of Q2 2022.
Emerson Wealth left its AbbVie share count unchanged in Q2 2022.
AbbVie made up 0.06% of Emerson Wealth's portfolio in Q2 2022, its #30 holding.
Emerson Wealth first reported a position in AbbVie in Q1 2022 and has held it in 2 quarters since.
Emerson Wealth's AbbVie position peaked at $97K in Q1 2022.
3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Emerson Wealth's 13F filing for Q2 2022, filed 3 Aug 2022.